Shandong Xinhua Pharmaceutical's Two Drugs Pass Chinese Drug Regulator's Consistency Evaluation

MT Newswires Live06-03

China's National Medical Products Administration approved Shandong Xinhua Pharmaceutical's (SHE:000756, HKG:0719) supplementary drug application for two of its drugs, the company said in filings published on the Hong Kong Stock Exchange.

The naloxone hydrochloride injection and citicoline sodium injection both passed the regulator's consistency evaluation for the drugs' quality and efficacy.

The drug regulator also approved applications to make changes to citicoline sodium injection's specifications, including the addition of 4 milligrams: 0.5 grams.

Shares of the company slipped less than 2% at the close.

Price (HKD): $15.34, Change: $-0.26, Percent Change: -1.67%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2440454693?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-03 16:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2440454693","market":"us","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical's Two Drugs Pass Chinese Drug Regulator's Consistency Evaluation","media":"MT Newswires Live","content":"<html><body><p> China's National Medical Products Administration approved Shandong Xinhua Pharmaceutical's (SHE:000756, HKG:0719) supplementary drug application for two of its drugs, the company said in filings published on the Hong Kong Stock Exchange. </p><p>The naloxone hydrochloride injection and citicoline sodium injection both passed the regulator's consistency evaluation for the drugs' quality and efficacy. </p><p>The drug regulator also approved applications to make changes to citicoline sodium injection's specifications, including the addition of 4 milligrams: 0.5 grams.</p><p>Shares of the company slipped less than 2% at the close. </p><p>Price (HKD): $15.34, Change: $-0.26, Percent Change: -1.67%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical's Two Drugs Pass Chinese Drug Regulator's Consistency Evaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical's Two Drugs Pass Chinese Drug Regulator's Consistency Evaluation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-03 16:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>China's National Medical Products Administration approved Shandong Xinhua Pharmaceutical's (SHE:000756, HKG:0719) supplementary drug application for two of its drugs, the company said in filings ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2440454693","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2440454693","pubTimestamp":1717405151,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's National Medical Products Administration approved Shandong Xinhua Pharmaceutical's  supplementary drug application for two of its drugs, the company said in filings published on the Hong Kong Stock Exchange. The naloxone hydrochloride injection and citicoline sodium injection both passed the regulator's consistency evaluation for the drugs' quality and efficacy. The drug regulator also approved applications to make changes to citicoline sodium injection's specifications, including the addition of 4 milligrams: 0.5 grams.Shares of the company slipped less than 2% at the close. Price : $15.34, Change: $-0.26, Percent Change: -1.67%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","BK4585":"ETF&股票定投概念","BK1515":"抗疫概念","BK1191":"制药","000756":"新华制药","BK4588":"碎股","HKD":"尚乘数科","00719":"山东新华制药股份","BK4023":"应用软件","BK4526":"热门中概股","BK0164":"国企混改"},"translate_title":"山东新华制药两款药品通过中国药监一致性评价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"000756":0.9,"00719":0.9},"content_text":"China's National Medical Products Administration approved Shandong Xinhua Pharmaceutical's (SHE:000756, HKG:0719) supplementary drug application for two of its drugs, the company said in filings published on the Hong Kong Stock Exchange. The naloxone hydrochloride injection and citicoline sodium injection both passed the regulator's consistency evaluation for the drugs' quality and efficacy. The drug regulator also approved applications to make changes to citicoline sodium injection's specifications, including the addition of 4 milligrams: 0.5 grams.Shares of the company slipped less than 2% at the close. Price (HKD): $15.34, Change: $-0.26, Percent Change: -1.67%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2440454693"}